Financial Performance - Goodyear reported a quarterly loss of $0.17 per share, missing the Zacks Consensus Estimate of $0.37, and compared to earnings of $0.19 per share a year ago, representing an earnings surprise of -145.95% [1] - The company posted revenues of $4.47 billion for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.83%, and down from $4.57 billion year-over-year [2] - Over the last four quarters, Goodyear has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Stock Performance and Outlook - Goodyear shares have increased approximately 10.4% since the beginning of the year, outperforming the S&P 500's gain of 7.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $0.50 on revenues of $4.82 billion, and for the current fiscal year, it is $1.31 on revenues of $18.57 billion [7] Industry Context - The Rubber - Tires industry, to which Goodyear belongs, is currently ranked in the bottom 6% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Goodyear's stock performance [5] - The unfavorable trend in estimate revisions prior to the earnings release has resulted in a Zacks Rank 5 (Strong Sell) for Goodyear, suggesting expected underperformance in the near future [6]

Company Performance - Owlet, Inc. reported a quarterly loss of $0.05 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.21, representing an earnings surprise of +76.19% [1] - The company posted revenues of $26.1 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 19.51% and up from $20.7 million a year ago [2] - Over the last four quarters, Owlet has surpassed consensus EPS estimates three times and topped revenue estimates two times [2] Stock Movement and Outlook - Owlet shares have increased approximately 59.6% since the beginning of the year, outperforming the S&P 500's gain of 7.9% [3] - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.24 on revenues of $23.45 million, and for the current fiscal year, it is -$1.03 on revenues of $93.02 million [7] Industry Context - The Technology Services industry, to which Owlet belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Owlet's performance [5][6]

分组1 - TripAdvisor reported quarterly earnings of $0.46 per share, exceeding the Zacks Consensus Estimate of $0.42 per share, and up from $0.39 per share a year ago, representing an earnings surprise of +9.52% [1] - The company posted revenues of $529 million for the quarter ended June 2025, which was slightly below the Zacks Consensus Estimate by 0.27%, but an increase from $497 million year-over-year [2] - TripAdvisor has surpassed consensus EPS estimates in all four of the last quarters and has topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has gained approximately 11.6% since the beginning of the year, outperforming the S&P 500's gain of 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is $0.62 on revenues of $572.28 million, and for the current fiscal year, it is $1.45 on revenues of $1.94 billion [7] - The Zacks Industry Rank indicates that the Internet - Commerce sector is currently in the bottom 34% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Core Insights - Sutro Biopharma, Inc. reported a quarterly loss of $0.14 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.39, and an improvement from a loss of $0.59 per share a year ago, resulting in an earnings surprise of +64.10% [1] - The company achieved revenues of $63.75 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 293.54%, compared to $25.71 million in the same quarter last year [2] - Sutro Biopharma's stock has declined approximately 55.6% year-to-date, contrasting with the S&P 500's gain of 7.9% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.24 on revenues of $14.66 million, and for the current fiscal year, it is -$1.79 on revenues of $62.76 million [7] Industry Context - Sutro Biopharma operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable industry outlook [8] - The performance of Sutro Biopharma's stock may be influenced by the overall industry trends, as historically, the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8] Estimate Revisions - The trend of estimate revisions for Sutro Biopharma was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market in the near future [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - Amphastar Pharmaceuticals reported quarterly earnings of $0.85 per share, exceeding the Zacks Consensus Estimate of $0.71 per share, but down from $0.94 per share a year ago, indicating an earnings surprise of +19.72% [1][2] Financial Performance - The company posted revenues of $174.41 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.69%, but down from $182.39 million year-over-year [2] - Over the last four quarters, Amphastar has surpassed consensus EPS estimates two times and topped consensus revenue estimates once [2] Stock Performance - Amphastar shares have declined approximately 43.9% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] Future Outlook - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at $0.83 for the coming quarter and $3.17 for the current fiscal year [7] - The Zacks Rank for Amphastar is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Industry Context - The Medical - Generic Drugs industry, to which Amphastar belongs, is currently in the bottom 34% of over 250 Zacks industries, suggesting potential challenges ahead [8]

分组1 - SolarEdge Technologies reported a quarterly loss of $0.81 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.82, and an improvement from a loss of $1.79 per share a year ago, indicating an earnings surprise of +1.22% [1] - The company posted revenues of $289.43 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.74% and showing an increase from year-ago revenues of $265.4 million [2] - SolarEdge shares have increased approximately 89.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.69 on revenues of $302.07 million, and for the current fiscal year, it is -$3.29 on revenues of $1.1 billion [7] - The Zacks Industry Rank indicates that the solar industry is currently in the bottom 39% of over 250 Zacks industries, which may impact stock performance [8] - Sunnova Energy, another company in the solar industry, is expected to report a quarterly loss of $0.71 per share, with revenues projected to be $266 million, reflecting a year-over-year increase of 21.1% [9]

Company Performance - Zimmer Biomet reported quarterly earnings of $2.07 per share, exceeding the Zacks Consensus Estimate of $1.98 per share, and showing an increase from $2.01 per share a year ago, resulting in an earnings surprise of +4.55% [1] - The company posted revenues of $2.08 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.59%, and an increase from $1.94 billion year-over-year [2] - Over the last four quarters, Zimmer has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance and Outlook - Zimmer shares have declined approximately 13.7% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $1.81 on revenues of $2 billion, and for the current fiscal year, it is $7.95 on revenues of $8.19 billion [7] Industry Context - The Medical - Products industry, to which Zimmer belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

Core Insights - ACI Worldwide reported quarterly earnings of $0.35 per share, exceeding the Zacks Consensus Estimate of $0.27 per share, but down from $0.47 per share a year ago, resulting in an earnings surprise of +29.63% [1] - The company achieved revenues of $401.26 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.44% and up from $373.48 million year-over-year [2] - ACI Worldwide has consistently surpassed consensus EPS estimates over the last four quarters [2] Financial Performance - The earnings surprise for the previous quarter was +54.55%, with actual earnings of $0.51 per share against an expected $0.33 [1] - The current consensus EPS estimate for the upcoming quarter is $0.91, with projected revenues of $446.9 million, and for the current fiscal year, the EPS estimate is $2.84 on revenues of $1.71 billion [7] Market Position - ACI Worldwide shares have declined approximately 18.8% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The Zacks Industry Rank places the Computer - Software sector in the top 35% of over 250 Zacks industries, indicating a favorable outlook for stocks in this sector [8] Future Outlook - The company's earnings outlook will be influenced by management's commentary during the earnings call and the trends in earnings estimate revisions [4][5] - ACI Worldwide currently holds a Zacks Rank 2 (Buy), suggesting that the shares are expected to outperform the market in the near future [6]

Core Viewpoint - Talen Energy Corporation reported quarterly earnings of $1.5 per share, significantly exceeding the Zacks Consensus Estimate of a loss of $1.13 per share, and showing a substantial increase from earnings of $0.19 per share a year ago [1][2]. Financial Performance - The earnings surprise for the quarter was +232.74%, with the company previously expected to post earnings of $1.17 per share but actually reporting $0.82, resulting in a surprise of -29.91% [2]. - Talen Energy's revenues for the quarter ended June 2025 were $630 million, surpassing the Zacks Consensus Estimate by 31.07%, compared to $489 million in the same quarter last year [3]. - Over the last four quarters, Talen Energy has exceeded consensus EPS estimates two times and has also topped consensus revenue estimates twice [2][3]. Stock Performance - Talen Energy shares have increased approximately 88% since the beginning of the year, outperforming the S&P 500, which gained 7.9% during the same period [4]. - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and future earnings expectations [4]. Future Outlook - The current consensus EPS estimate for the upcoming quarter is $4.47, with expected revenues of $736.04 million, and for the current fiscal year, the estimate remains at $4.47 with revenues projected at $2.3 billion [8]. - The estimate revisions trend for Talen Energy was favorable ahead of the earnings release, resulting in a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [7]. Industry Context - The Alternative Energy - Other industry, to which Talen Energy belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, suggesting that the overall industry outlook may impact stock performance [9].

Core Insights - GoodRx Holdings, Inc. (GDRX) reported revenue of $203.07 million for the quarter ended June 2025, reflecting a 1.2% increase year-over-year, while EPS was $0.09, up from $0.08 in the same quarter last year [1] - The reported revenue fell short of the Zacks Consensus Estimate of $205.18 million, resulting in a surprise of -1.03%, and the EPS also missed the consensus estimate of $0.10 by 10% [1] Financial Performance Metrics - Monthly Active Consumers stood at 6, matching the average estimate from three analysts [4] - Subscription plans totaled 668, slightly below the two-analyst average estimate of 677 [4] - Revenue from prescription transactions was $143.06 million, which was lower than the estimated $148.77 million, marking a -2.5% change year-over-year [4] - Revenue from other sources was $4.56 million, compared to the average estimate of $4.63 million, representing a -15.5% year-over-year change [4] - Revenue from pharma manufacturer solutions reached $34.98 million, exceeding the average estimate of $31.54 million, showing a +32% year-over-year increase [4] - Subscription revenue was reported at $20.46 million, below the estimated $20.93 million, reflecting a -7% change compared to the previous year [4] Stock Performance - GoodRx shares have declined by -9.3% over the past month, contrasting with a +0.5% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]